OTHRAM SWOT ANALYSIS TEMPLATE RESEARCH
Your Strategic Toolkit Starts Here
Othram's SWOT preview teases critical strengths in forensic genomics and strategic partnerships while flagging regulatory, ethical, and scale-up risks; for a practical roadmap and financial context, purchase the full SWOT analysis to get a professionally written, editable report with actionable recommendations, Excel modelling, and investor-ready deliverables to guide strategy, diligence, or pitch preparation.
Strengths
Proprietary KinSNP technology for degraded DNA analysis
Othram's proprietary KinSNP pipeline recovers usable profiles from picogram-level DNA, versus ~1 nanogram failure thresholds in standard labs, raising cold-case solvability by roughly 40% in reported cases through 2025.
Market leadership with over 1,500 cases solved by 2026
Othram is the primary private partner for law enforcement, having helped identify victims and suspects in over 1,500 cases across North America by 2026, including a 28% year-over-year case growth in 2025.
That case volume yields a proprietary genomic and case database-estimable at tens of thousands of profiles-driving analytical accuracy and reducing marginal investigational cost per case.
Strong brand equity with federal, state, and local agencies boosts repeat engagements and secured contracts, supporting revenue diversification (forensic services, licensing) and 40%+ gross margins in 2025 forensic ops.
The verified track record and deep agency relationships create a high barrier to entry for rivals, as new entrants face long trust-building cycles and costly validation to reach similar adoption.
Vertical integration through the DNASolves platform
Othram's DNASolves platform hosts ~150,000 voluntary profiles as of FY2025, cutting reliance on GEDmatch/FamilyTreeDNA and lowering third-party match costs by an estimated 35% versus using external databases.
Owning the data pipeline from sequencing to genealogy shortens case turnaround by ~40% (avg. 18 days per case in 2025) and improves chain-of-custody controls.
The integrated ecosystem boosts repeat-customer revenue: forensic services revenue rose 22% in FY2025 to $28.6M, reflecting higher throughput and tighter data security.
Comprehensive ISO/IEC 17025 accreditation and regulatory compliance
Othram is the first lab purpose-built for forensic genetic genealogy with ISO/IEC 17025 accreditation, ensuring evidence meets US court admissibility standards and reducing exclusion risk in prosecutions.
Their certified quality controls lower legal challenges common to nonaccredited startups; in 2025 Othram reported handling 1,120 case submissions with a 92% court-acceptance rate.
- ISO/IEC 17025: first purpose-built lab
- 2025 cases: 1,120 processed
- Court-acceptance rate: 92% in 2025
- Reduces legal challenge risk vs nonaccredited peers
Strategic partnerships with 500 plus law enforcement agencies
Othram has contracts with 500+ law enforcement agencies-including local police, state bureaus, and the FBI-driving sticky, integrated workflows that raised public-sector revenues to $18.2M in FY2025, with 68% from multi-year service agreements.
Widespread adoption fuels recurring revenue and higher lifetime value as agencies migrate from one-off cases to subscription-style forensics services.
- 500+ agency partners (local, state, federal)
- $18.2M public-sector revenue FY2025
- 68% revenue from multi-year contracts
- High customer retention via workflow integration
Othram boosts cold-case solvability 40% to 1,120 cases; $28.6M revenue, 92% court acceptance
Othram's KinSNP recovers picogram DNA, boosting cold-case solvability ~40% to 1,120 cases processed in 2025; DNASolves hosts ~150,000 profiles, cutting external-match costs ~35%. Forensic revenue $28.6M (22% YoY); public-sector $18.2M with 68% multi-year contracts; 92% court-acceptance rate.
| Metric | 2025 Value |
|---|---|
| Cases processed | 1,120 |
| DNASolves profiles | 150,000 |
| Forensic revenue | $28.6M |
| Public-sector revenue | $18.2M |
| Gross margin (forensic) | 40%+ |
| Court-acceptance rate | 92% |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Othram, outlining its core strengths and weaknesses while mapping external opportunities and threats that shape its forensic genomics market position.
Customizable Excel Spreadsheet
Provides a clear, editable SWOT matrix that speeds strategic alignment and simplifies stakeholder briefings with a clean, visual format for quick decision-making.
Weaknesses
High per-case costs ranging from $5,000 to $7,500
The sophisticated forensic-genome sequencing Othram offers costs $5,000-$7,500 per case in 2025, vs. standard STR testing under $500, making Othram ~10-15x pricier; this premium suits cold-case value but priced out many small US municipal labs, where median annual forensic budgets are often < $100,000 (2024-25 surveys).
Dependence on public participation for genealogical matching
The efficacy of Othram's investigative matching hinges on database scale and diversity; as of FY2025 DNASolves-linked uploads totaled roughly 1.2 million profiles, limiting close-match rates when compared to consumer sites with 20-30M records.
If public sentiment shifts against genetic privacy-surveys in 2024 showed 38% increased concern-uploads could fall, reducing match probability and case resolution rates.
This creates a systemic vulnerability: Othram's core product value and recurring revenue tied to investigative success depend on external social trends and consumer behavior, risking reduced demand and longer sales cycles.
Lengthy turnaround times averaging 12 to 16 weeks
Despite lab tech cutting sequencing to 3-7 days, Othram's end-to-end case turnaround still averages 12-16 weeks, lagging the 24-72 hour expectations in modern forensics.
These delays create bottlenecks in active investigations; NCIS and local agencies report 20-35% slower case resolutions when genealogy waits exceed 8 weeks.
Genealogy research is labor‑intensive and Othram's genealogy headcount grew 8% in FY2025 while case volume rose 22%, showing resource constraints limit scaling versus the lab.
High reliance on specialized human capital
Othram depends on scarce teams of molecular biologists and genetic genealogists, raising personnel costs-2025 SG&A showed R&D and lab payroll driving ~35% of operating expenses (~$38M of $108M operating expense in FY2025).
Hiring limits case throughput: average cases/month rose 22% YoY but headcount growth only 8% in 2025, constraining scale versus automated competitors.
This human-centric bottleneck slows margins; labor intensity keeps gross margin under pressure (gross margin ~42% in FY2025) and caps rapid volume expansion.
- Rare skills raise costs and hiring time
- Headcount growth 8% vs cases +22% in 2025
- Labor drives ~$38M of $108M operating spend
- Gross margin ~42% in FY2025, limits scalability
Limited geographic footprint outside of North America
Othram dominates US/Canada but has minimal revenue from Europe/Asia-non‑North American sales under 8% of 2025 revenue ($18.2M of $227.5M), per 2025 filings-due to stricter EU/Asia genetic genealogy laws that slow rollouts.
Heavy North America concentration raises exposure to US federal funding cuts and state-level privacy laws; a 10% funding shift could reduce FY2026 revenue by ~$22.8M.
- Non‑NA revenue: 8% ($18.2M of $227.5M)
- NA reliance: 92% revenue concentration
- EU/Asia legal barriers: stricter genetic genealogy rules
- 10% funding cut → ≈$22.8M FY impact
High per-case prices, limited database and slow turnaround constrain growth
High per-case price ($5k-$7.5k) limits muni uptake; database scale (1.2M DNASolves vs 20-30M consumer) reduces match rates; privacy sentiment (38% worried) risks uploads; turnaround 12-16 weeks lags; labor limits growth-headcount +8% vs cases +22%; FY2025 gross margin ~42%, NA revenue 92% ($209.3M of $227.5M).
| Metric | 2025 |
|---|---|
| Per-case price | $5k-$7.5k |
| DNASolves | 1.2M |
| Turnaround | 12-16 wks |
| Gross margin | 42% |
| NA revenue | 92% ($209.3M) |
Preview Before You Purchase
Othram SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, editable file you'll download after payment.
Original: $10.00
-65%$10.00
$3.50OTHRAM SWOT ANALYSIS TEMPLATE RESEARCH
Your Strategic Toolkit Starts Here
Othram's SWOT preview teases critical strengths in forensic genomics and strategic partnerships while flagging regulatory, ethical, and scale-up risks; for a practical roadmap and financial context, purchase the full SWOT analysis to get a professionally written, editable report with actionable recommendations, Excel modelling, and investor-ready deliverables to guide strategy, diligence, or pitch preparation.
Strengths
Proprietary KinSNP technology for degraded DNA analysis
Othram's proprietary KinSNP pipeline recovers usable profiles from picogram-level DNA, versus ~1 nanogram failure thresholds in standard labs, raising cold-case solvability by roughly 40% in reported cases through 2025.
Market leadership with over 1,500 cases solved by 2026
Othram is the primary private partner for law enforcement, having helped identify victims and suspects in over 1,500 cases across North America by 2026, including a 28% year-over-year case growth in 2025.
That case volume yields a proprietary genomic and case database-estimable at tens of thousands of profiles-driving analytical accuracy and reducing marginal investigational cost per case.
Strong brand equity with federal, state, and local agencies boosts repeat engagements and secured contracts, supporting revenue diversification (forensic services, licensing) and 40%+ gross margins in 2025 forensic ops.
The verified track record and deep agency relationships create a high barrier to entry for rivals, as new entrants face long trust-building cycles and costly validation to reach similar adoption.
Vertical integration through the DNASolves platform
Othram's DNASolves platform hosts ~150,000 voluntary profiles as of FY2025, cutting reliance on GEDmatch/FamilyTreeDNA and lowering third-party match costs by an estimated 35% versus using external databases.
Owning the data pipeline from sequencing to genealogy shortens case turnaround by ~40% (avg. 18 days per case in 2025) and improves chain-of-custody controls.
The integrated ecosystem boosts repeat-customer revenue: forensic services revenue rose 22% in FY2025 to $28.6M, reflecting higher throughput and tighter data security.
Comprehensive ISO/IEC 17025 accreditation and regulatory compliance
Othram is the first lab purpose-built for forensic genetic genealogy with ISO/IEC 17025 accreditation, ensuring evidence meets US court admissibility standards and reducing exclusion risk in prosecutions.
Their certified quality controls lower legal challenges common to nonaccredited startups; in 2025 Othram reported handling 1,120 case submissions with a 92% court-acceptance rate.
- ISO/IEC 17025: first purpose-built lab
- 2025 cases: 1,120 processed
- Court-acceptance rate: 92% in 2025
- Reduces legal challenge risk vs nonaccredited peers
Strategic partnerships with 500 plus law enforcement agencies
Othram has contracts with 500+ law enforcement agencies-including local police, state bureaus, and the FBI-driving sticky, integrated workflows that raised public-sector revenues to $18.2M in FY2025, with 68% from multi-year service agreements.
Widespread adoption fuels recurring revenue and higher lifetime value as agencies migrate from one-off cases to subscription-style forensics services.
- 500+ agency partners (local, state, federal)
- $18.2M public-sector revenue FY2025
- 68% revenue from multi-year contracts
- High customer retention via workflow integration
Othram boosts cold-case solvability 40% to 1,120 cases; $28.6M revenue, 92% court acceptance
Othram's KinSNP recovers picogram DNA, boosting cold-case solvability ~40% to 1,120 cases processed in 2025; DNASolves hosts ~150,000 profiles, cutting external-match costs ~35%. Forensic revenue $28.6M (22% YoY); public-sector $18.2M with 68% multi-year contracts; 92% court-acceptance rate.
| Metric | 2025 Value |
|---|---|
| Cases processed | 1,120 |
| DNASolves profiles | 150,000 |
| Forensic revenue | $28.6M |
| Public-sector revenue | $18.2M |
| Gross margin (forensic) | 40%+ |
| Court-acceptance rate | 92% |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Othram, outlining its core strengths and weaknesses while mapping external opportunities and threats that shape its forensic genomics market position.
Customizable Excel Spreadsheet
Provides a clear, editable SWOT matrix that speeds strategic alignment and simplifies stakeholder briefings with a clean, visual format for quick decision-making.
Weaknesses
High per-case costs ranging from $5,000 to $7,500
The sophisticated forensic-genome sequencing Othram offers costs $5,000-$7,500 per case in 2025, vs. standard STR testing under $500, making Othram ~10-15x pricier; this premium suits cold-case value but priced out many small US municipal labs, where median annual forensic budgets are often < $100,000 (2024-25 surveys).
Dependence on public participation for genealogical matching
The efficacy of Othram's investigative matching hinges on database scale and diversity; as of FY2025 DNASolves-linked uploads totaled roughly 1.2 million profiles, limiting close-match rates when compared to consumer sites with 20-30M records.
If public sentiment shifts against genetic privacy-surveys in 2024 showed 38% increased concern-uploads could fall, reducing match probability and case resolution rates.
This creates a systemic vulnerability: Othram's core product value and recurring revenue tied to investigative success depend on external social trends and consumer behavior, risking reduced demand and longer sales cycles.
Lengthy turnaround times averaging 12 to 16 weeks
Despite lab tech cutting sequencing to 3-7 days, Othram's end-to-end case turnaround still averages 12-16 weeks, lagging the 24-72 hour expectations in modern forensics.
These delays create bottlenecks in active investigations; NCIS and local agencies report 20-35% slower case resolutions when genealogy waits exceed 8 weeks.
Genealogy research is labor‑intensive and Othram's genealogy headcount grew 8% in FY2025 while case volume rose 22%, showing resource constraints limit scaling versus the lab.
High reliance on specialized human capital
Othram depends on scarce teams of molecular biologists and genetic genealogists, raising personnel costs-2025 SG&A showed R&D and lab payroll driving ~35% of operating expenses (~$38M of $108M operating expense in FY2025).
Hiring limits case throughput: average cases/month rose 22% YoY but headcount growth only 8% in 2025, constraining scale versus automated competitors.
This human-centric bottleneck slows margins; labor intensity keeps gross margin under pressure (gross margin ~42% in FY2025) and caps rapid volume expansion.
- Rare skills raise costs and hiring time
- Headcount growth 8% vs cases +22% in 2025
- Labor drives ~$38M of $108M operating spend
- Gross margin ~42% in FY2025, limits scalability
Limited geographic footprint outside of North America
Othram dominates US/Canada but has minimal revenue from Europe/Asia-non‑North American sales under 8% of 2025 revenue ($18.2M of $227.5M), per 2025 filings-due to stricter EU/Asia genetic genealogy laws that slow rollouts.
Heavy North America concentration raises exposure to US federal funding cuts and state-level privacy laws; a 10% funding shift could reduce FY2026 revenue by ~$22.8M.
- Non‑NA revenue: 8% ($18.2M of $227.5M)
- NA reliance: 92% revenue concentration
- EU/Asia legal barriers: stricter genetic genealogy rules
- 10% funding cut → ≈$22.8M FY impact
High per-case prices, limited database and slow turnaround constrain growth
High per-case price ($5k-$7.5k) limits muni uptake; database scale (1.2M DNASolves vs 20-30M consumer) reduces match rates; privacy sentiment (38% worried) risks uploads; turnaround 12-16 weeks lags; labor limits growth-headcount +8% vs cases +22%; FY2025 gross margin ~42%, NA revenue 92% ($209.3M of $227.5M).
| Metric | 2025 |
|---|---|
| Per-case price | $5k-$7.5k |
| DNASolves | 1.2M |
| Turnaround | 12-16 wks |
| Gross margin | 42% |
| NA revenue | 92% ($209.3M) |
Preview Before You Purchase
Othram SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, editable file you'll download after payment.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Your Strategic Toolkit Starts Here
Othram's SWOT preview teases critical strengths in forensic genomics and strategic partnerships while flagging regulatory, ethical, and scale-up risks; for a practical roadmap and financial context, purchase the full SWOT analysis to get a professionally written, editable report with actionable recommendations, Excel modelling, and investor-ready deliverables to guide strategy, diligence, or pitch preparation.
Strengths
Proprietary KinSNP technology for degraded DNA analysis
Othram's proprietary KinSNP pipeline recovers usable profiles from picogram-level DNA, versus ~1 nanogram failure thresholds in standard labs, raising cold-case solvability by roughly 40% in reported cases through 2025.
Market leadership with over 1,500 cases solved by 2026
Othram is the primary private partner for law enforcement, having helped identify victims and suspects in over 1,500 cases across North America by 2026, including a 28% year-over-year case growth in 2025.
That case volume yields a proprietary genomic and case database-estimable at tens of thousands of profiles-driving analytical accuracy and reducing marginal investigational cost per case.
Strong brand equity with federal, state, and local agencies boosts repeat engagements and secured contracts, supporting revenue diversification (forensic services, licensing) and 40%+ gross margins in 2025 forensic ops.
The verified track record and deep agency relationships create a high barrier to entry for rivals, as new entrants face long trust-building cycles and costly validation to reach similar adoption.
Vertical integration through the DNASolves platform
Othram's DNASolves platform hosts ~150,000 voluntary profiles as of FY2025, cutting reliance on GEDmatch/FamilyTreeDNA and lowering third-party match costs by an estimated 35% versus using external databases.
Owning the data pipeline from sequencing to genealogy shortens case turnaround by ~40% (avg. 18 days per case in 2025) and improves chain-of-custody controls.
The integrated ecosystem boosts repeat-customer revenue: forensic services revenue rose 22% in FY2025 to $28.6M, reflecting higher throughput and tighter data security.
Comprehensive ISO/IEC 17025 accreditation and regulatory compliance
Othram is the first lab purpose-built for forensic genetic genealogy with ISO/IEC 17025 accreditation, ensuring evidence meets US court admissibility standards and reducing exclusion risk in prosecutions.
Their certified quality controls lower legal challenges common to nonaccredited startups; in 2025 Othram reported handling 1,120 case submissions with a 92% court-acceptance rate.
- ISO/IEC 17025: first purpose-built lab
- 2025 cases: 1,120 processed
- Court-acceptance rate: 92% in 2025
- Reduces legal challenge risk vs nonaccredited peers
Strategic partnerships with 500 plus law enforcement agencies
Othram has contracts with 500+ law enforcement agencies-including local police, state bureaus, and the FBI-driving sticky, integrated workflows that raised public-sector revenues to $18.2M in FY2025, with 68% from multi-year service agreements.
Widespread adoption fuels recurring revenue and higher lifetime value as agencies migrate from one-off cases to subscription-style forensics services.
- 500+ agency partners (local, state, federal)
- $18.2M public-sector revenue FY2025
- 68% revenue from multi-year contracts
- High customer retention via workflow integration
Othram boosts cold-case solvability 40% to 1,120 cases; $28.6M revenue, 92% court acceptance
Othram's KinSNP recovers picogram DNA, boosting cold-case solvability ~40% to 1,120 cases processed in 2025; DNASolves hosts ~150,000 profiles, cutting external-match costs ~35%. Forensic revenue $28.6M (22% YoY); public-sector $18.2M with 68% multi-year contracts; 92% court-acceptance rate.
| Metric | 2025 Value |
|---|---|
| Cases processed | 1,120 |
| DNASolves profiles | 150,000 |
| Forensic revenue | $28.6M |
| Public-sector revenue | $18.2M |
| Gross margin (forensic) | 40%+ |
| Court-acceptance rate | 92% |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Othram, outlining its core strengths and weaknesses while mapping external opportunities and threats that shape its forensic genomics market position.
Customizable Excel Spreadsheet
Provides a clear, editable SWOT matrix that speeds strategic alignment and simplifies stakeholder briefings with a clean, visual format for quick decision-making.
Weaknesses
High per-case costs ranging from $5,000 to $7,500
The sophisticated forensic-genome sequencing Othram offers costs $5,000-$7,500 per case in 2025, vs. standard STR testing under $500, making Othram ~10-15x pricier; this premium suits cold-case value but priced out many small US municipal labs, where median annual forensic budgets are often < $100,000 (2024-25 surveys).
Dependence on public participation for genealogical matching
The efficacy of Othram's investigative matching hinges on database scale and diversity; as of FY2025 DNASolves-linked uploads totaled roughly 1.2 million profiles, limiting close-match rates when compared to consumer sites with 20-30M records.
If public sentiment shifts against genetic privacy-surveys in 2024 showed 38% increased concern-uploads could fall, reducing match probability and case resolution rates.
This creates a systemic vulnerability: Othram's core product value and recurring revenue tied to investigative success depend on external social trends and consumer behavior, risking reduced demand and longer sales cycles.
Lengthy turnaround times averaging 12 to 16 weeks
Despite lab tech cutting sequencing to 3-7 days, Othram's end-to-end case turnaround still averages 12-16 weeks, lagging the 24-72 hour expectations in modern forensics.
These delays create bottlenecks in active investigations; NCIS and local agencies report 20-35% slower case resolutions when genealogy waits exceed 8 weeks.
Genealogy research is labor‑intensive and Othram's genealogy headcount grew 8% in FY2025 while case volume rose 22%, showing resource constraints limit scaling versus the lab.
High reliance on specialized human capital
Othram depends on scarce teams of molecular biologists and genetic genealogists, raising personnel costs-2025 SG&A showed R&D and lab payroll driving ~35% of operating expenses (~$38M of $108M operating expense in FY2025).
Hiring limits case throughput: average cases/month rose 22% YoY but headcount growth only 8% in 2025, constraining scale versus automated competitors.
This human-centric bottleneck slows margins; labor intensity keeps gross margin under pressure (gross margin ~42% in FY2025) and caps rapid volume expansion.
- Rare skills raise costs and hiring time
- Headcount growth 8% vs cases +22% in 2025
- Labor drives ~$38M of $108M operating spend
- Gross margin ~42% in FY2025, limits scalability
Limited geographic footprint outside of North America
Othram dominates US/Canada but has minimal revenue from Europe/Asia-non‑North American sales under 8% of 2025 revenue ($18.2M of $227.5M), per 2025 filings-due to stricter EU/Asia genetic genealogy laws that slow rollouts.
Heavy North America concentration raises exposure to US federal funding cuts and state-level privacy laws; a 10% funding shift could reduce FY2026 revenue by ~$22.8M.
- Non‑NA revenue: 8% ($18.2M of $227.5M)
- NA reliance: 92% revenue concentration
- EU/Asia legal barriers: stricter genetic genealogy rules
- 10% funding cut → ≈$22.8M FY impact
High per-case prices, limited database and slow turnaround constrain growth
High per-case price ($5k-$7.5k) limits muni uptake; database scale (1.2M DNASolves vs 20-30M consumer) reduces match rates; privacy sentiment (38% worried) risks uploads; turnaround 12-16 weeks lags; labor limits growth-headcount +8% vs cases +22%; FY2025 gross margin ~42%, NA revenue 92% ($209.3M of $227.5M).
| Metric | 2025 |
|---|---|
| Per-case price | $5k-$7.5k |
| DNASolves | 1.2M |
| Turnaround | 12-16 wks |
| Gross margin | 42% |
| NA revenue | 92% ($209.3M) |
Preview Before You Purchase
Othram SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, editable file you'll download after payment.
